Literature DB >> 7504576

Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial.

M Belehradek1, C Domenge, B Luboinski, S Orlowski, J Belehradek, L M Mir.   

Abstract

BACKGROUND: Electrochemotherapy is a new antitumor treatment consisting of electrical pulses administered to the tumor several minutes after intravenous injection of bleomycin. In mice, important antitumor effects were observed on subcutaneously transplanted tumors and on spontaneously occurring mammary carcinomas. Cures were obtained after one single treatment combining bleomycin and electric pulses. In humans, permeation nodules seemed an adequate oncologic situation to assay this new procedure. The authors report the first Phase I-II trial of electrochemotherapy.
METHODS: Eight patients with 40 permeation nodules of head and neck squamous cell carcinomas were treated with 10 mg/m2 bleomycin intravenous bolus, followed by four or eight short (100 microseconds) and intense (1300 V/cm) pulses administered through two external electrodes located on each side of the treated nodule.
RESULTS: An instantaneous painless contraction of the underlying muscles was regularly observed. Neither local nor general side effects were observed, and electrochemotherapy was well tolerated. In addition, a clear local antitumor efficacy was found: 23 (57%) nodules were in clinical complete response within a few days.
CONCLUSION: The absence of toxicity, the good tolerance by the patients, and the net antitumor effects observed are encouraging for additional electrochemotherapy developments in clinical oncology.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504576     DOI: 10.1002/1097-0142(19931215)72:12<3694::aid-cncr2820721222>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  86 in total

1.  Electroporation-based technologies and treatments.

Authors:  Damijan Miklavcic; Lluis M Mir; P Thomas Vernier
Journal:  J Membr Biol       Date:  2010-07       Impact factor: 1.843

2.  Calcium electroporation induces tumor eradication, long-lasting immunity and cytokine responses in the CT26 colon cancer mouse model.

Authors:  Hanne Falk; Patrick F Forde; Marie Lund Bay; Uma Maheswari Mangalanathan; Pernille Hojman; Declan M Soden; Julie Gehl
Journal:  Oncoimmunology       Date:  2017-03-17       Impact factor: 8.110

Review 3.  Membrane perturbation by an external electric field: a mechanism to permit molecular uptake.

Authors:  J-M Escoffre; D S Dean; M Hubert; M-P Rols; C Favard
Journal:  Eur Biophys J       Date:  2007-06-19       Impact factor: 1.733

Review 4.  What is (still not) known of the mechanism by which electroporation mediates gene transfer and expression in cells and tissues.

Authors:  Jean-Michel Escoffre; Thomas Portet; Luc Wasungu; Justin Teissié; David Dean; Marie-Pierre Rols
Journal:  Mol Biotechnol       Date:  2008-11-18       Impact factor: 2.695

5.  Nanosecond electric pulses affect a plant-specific kinesin at the plasma membrane.

Authors:  Sebastian Kühn; Qiong Liu; Christian Eing; Wolfgang Frey; Peter Nick
Journal:  J Membr Biol       Date:  2013-09-24       Impact factor: 1.843

Review 6.  Nucleic acids electrotransfer-based gene therapy (electrogenetherapy): past, current, and future.

Authors:  L M Mir
Journal:  Mol Biotechnol       Date:  2009-06-27       Impact factor: 2.695

7.  Electrochemotherapy treatment of locally advanced and metastatic soft tissue sarcomas: results of a non-comparative phase II study.

Authors:  Luca G Campana; Giuseppe Bianchi; Simone Mocellin; Sara Valpione; Laura Campanacci; Antonella Brunello; Davide Donati; Elisabetta Sieni; Carlo R Rossi
Journal:  World J Surg       Date:  2014-04       Impact factor: 3.352

8.  Poloxamer 188 decreases susceptibility of artificial lipid membranes to electroporation.

Authors:  V Sharma; K Stebe; J C Murphy; L Tung
Journal:  Biophys J       Date:  1996-12       Impact factor: 4.033

9.  Electrochemotherapy significantly inhibits the growth of colon 26 tumors in mice.

Authors:  T Tada; K Matsumoto; H Suzuki
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

Review 10.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.